Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | P4HTM | Q9NXG6 | 11/20 | 0.59 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.59 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901156 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| Hydrochloric Acid SCHEMBL5934153 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| Lithium Ion SCHEMBL3901152 | 0.96 | KDM4E (0.92) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL16070636 | 0.83 | ALDH1A1 (0.70) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL471438 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL27660665 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL157129 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL29539391 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL787729 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL21811095 | 0.79 | KDM4E (0.63) | KDM4EALDH1A1P4HTMP4HA1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1850 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192071-A | Preparation method of 5-bromopyridine-2-carboxylic acid methyl ester | 济南泺合医药技术有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118160828-B | Feed additive for improving reproductive capacity of livestock and poultry and preparation method thereof | 潍坊海纳生物科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118160828-A | Feed additive for improving reproductive capacity of livestock and poultry and preparation method thereof | 潍坊海纳生物科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-115869923-B | Oxygen absorbing material, preparation method thereof and prepared adsorption material capable of simultaneously adsorbing oxygen and organic solvent | 威格科技(苏州)股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-110204484-B | The method comprises the following steps of 18 F-labeled fluoropyridine formylglycine, and preparation method and application thereof | 山西医科大学第一医院 | 2023-07-21 | — | — | CN | claimed |
| CN-116472064-A | Antibody-drug conjugates and uses thereof | 昆山新蕴达生物科技有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | claimed |
| CN-115869923-A | Oxygen absorbing material, preparation method thereof and prepared adsorbing material capable of adsorbing oxygen and organic solvent simultaneously | 威格科技(苏州)股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| WO-2022078279-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 昆山新蕴达生物科技有限公司 | 2022-04-21 | — | — | WO | claimed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | KDM4E 1864/4885ALDH1A1 440/4885P4HTM 1684/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | KDM4E 3048/4885ALDH1A1 834/4885P4HTM 544/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | KDM4E 1203/4885ALDH1A1 100/4885P4HTM 257/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | KDM4E 1864/4885ALDH1A1 440/4885P4HTM 1684/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | KDM4E 935/4885ALDH1A1 114/4885P4HTM 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.